{"id":38499,"date":"2026-04-30T10:48:00","date_gmt":"2026-04-30T14:48:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=38499"},"modified":"2026-04-27T09:05:06","modified_gmt":"2026-04-27T13:05:06","slug":"new-drug-old-molecule-how-pharma-extracts-billions-from-mature-drugs-through-new-indications","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/new-drug-old-molecule-how-pharma-extracts-billions-from-mature-drugs-through-new-indications\/","title":{"rendered":"New Drug, Old Molecule: How Pharma Extracts Billions from Mature Drugs Through New Indications"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Methods-of-use patents have quietly become the pharmaceutical industry’s most underappreciated exclusivity tool. Here’s how they work, who’s using them, and how to track them before your competitors do.<\/em><\/p>\n\n\n\n

\n\n\n\n

The Dirty Secret Behind Drug Patent Cliffs<\/strong><\/h2>\n\n\n\n

Every pharmaceutical executive dreads the patent cliff. The moment a compound patent expires, the economics of a blockbuster drug collapse within months. Generic manufacturers file abbreviated new drug applications (ANDAs), prices drop 80 to 90 percent, and branded revenue evaporates. The company that spent a decade and north of two billion dollars developing the drug watches it become a commodity.<\/p>\n\n\n\n

Except that’s not always how the story ends.<\/p>\n\n\n\n

A quieter but increasingly aggressive strategy has taken hold across the industry: returning to the clinic with a mature molecule, running trials in a new patient population or disease context, winning regulatory approval, and securing a fresh package of intellectual property. The compound patent may be dead. The regulatory exclusivity on the new indication is very much alive.<\/p>\n\n\n\n

This is the world of methods-of-use patents, and it has reshaped how the pharmaceutical industry thinks about asset lifecycles. It has also generated substantial litigation, shaped the biosimilar and generic entry timelines for dozens of drugs, and created a category of IP that most analysts undervalue until it’s too late to respond.<\/p>\n\n\n\n

This article examines the mechanics of indication expansion, the exclusivity tools that support it, the competitive dynamics it produces, and the real-world cases where companies have executed it well or stumbled badly. It also covers how databases like DrugPatentWatch are changing the way companies, investors, and litigators analyze these strategies in real time.<\/p>\n\n\n\n

\n\n\n\n

What Methods-of-Use Patents Actually Cover<\/strong><\/h2>\n\n\n\n

The Statutory Basis<\/strong><\/h3>\n\n\n\n

Under U.S. patent law, specifically 35 U.S.C. \u00a7 101, patentable subject matter includes processes, which encompasses methods of using a known compound to achieve a therapeutic outcome. A patent claiming ‘a method of treating Type 2 diabetes by administering compound X’ is legally distinct from a patent covering compound X itself. The compound may be off-patent. The method is not.<\/p>\n\n\n\n

This distinction sounds academic until you trace its commercial consequences. Methods-of-use patents can be listed in the FDA’s Orange Book for small-molecule drugs or Purple Book for biologics, provided they claim an approved method of using the drug. A generic or biosimilar manufacturer that wants to avoid those patents must either design around the claimed method, wait for expiration, or file a paragraph IV certification challenging validity or non-infringement. Each option carries cost and risk.<\/p>\n\n\n\n

The result is that a drug can carry a compound patent expiring in, say, 2024, but also carry a constellation of method-of-use patents expiring in 2031, 2033, and 2036, each tied to a different approved indication. The compound patent cliff becomes a staircase.<\/p>\n\n\n\n

How They Differ from Formulation and Process Patents<\/strong><\/h3>\n\n\n\n

Pharmaceutical companies use several distinct patent categories to extend exclusivity. Formulation patents cover specific delivery mechanisms, such as extended-release coatings, specific salt forms, or combination tablet compositions. Process patents cover manufacturing methods. Methods-of-use patents cover the clinical act of prescribing and taking the drug for a defined therapeutic purpose.<\/p>\n\n\n\n

Of these, methods-of-use patents are uniquely tied to regulatory approval. They only get listed in the Orange Book if the FDA has approved the underlying indication. That means the clock on their protection does not start running until the drug has a real, validated market for the new use. Formulation patents can be filed speculatively. Method-of-use patents require clinical proof.<\/p>\n\n\n\n

That connection to regulatory approval makes them both stronger and more expensive to obtain. The company has to run the trials, generate the data, and win the sNDA or sBLA. The IP protection is the downstream benefit, not the input.<\/p>\n\n\n\n

\n\n\n\n

The Regulatory Exclusivity Layer<\/strong><\/h2>\n\n\n\n

NCE, NME, and the Distinction That Matters<\/strong><\/h3>\n\n\n\n

Patents are not the only mechanism providing exclusivity for new indications. The Hatch-Waxman Act and the Biologics Price Competition and Innovation Act (BPCIA) created statutory exclusivity periods that function independently of patents.<\/p>\n\n\n\n

For small molecules, a supplemental new drug application (sNDA) for a new indication does not automatically grant five-year new chemical entity (NCE) exclusivity, which applies only to truly novel active ingredients. What it can grant is three years of exclusivity under the ‘new clinical investigation’ provision of 21 U.S.C. \u00a7 355(j)(5)(F)(iii), commonly called ‘three-year exclusivity.’ This applies when the new approval required conducting new clinical trials essential to the approval. It is not negligible: it gives the brand three years during which generic applicants cannot get final approval for the new indication, even if their ANDAs were already approved for prior indications.<\/p>\n\n\n\n

For biologics, the BPCIA provides 12 years of reference product exclusivity from original approval, but supplemental approvals for new indications do not reset that clock. What they can do is extend the commercial rationale for the product and, critically, add new method-of-use patents to the relevant Purple Book listings.<\/p>\n\n\n\n

Orphan Drug Designation as an Indication Strategy<\/strong><\/h3>\n\n\n\n

Orphan drug designation deserves particular attention here, because it is one of the most strategically underappreciated tools in this space.<\/p>\n\n\n\n

Under the Orphan Drug Act, a drug approved for a disease affecting fewer than 200,000 patients in the United States receives seven years of orphan exclusivity for that specific indication. That exclusivity blocks FDA from approving the same drug for the same rare disease for a competitor, including for a generic manufacturer seeking to claim that indication in their ANDA labeling.<\/p>\n\n\n\n

Companies have used this mechanism to carve out protected positions in rare disease subpopulations while their primary indication faces generic competition. Cystic fibrosis drugs, certain oncology agents treating rare tumor types, and specific neuromuscular disease treatments have all benefited from this approach.<\/p>\n\n\n\n

Ibuprofen for patent ductus arteriosus. Thalidomide for multiple myeloma. Colchicine, which had been used off-label for decades, received FDA approval and orphan exclusivity for familial Mediterranean fever and was marketed as Colcrys by URL Pharma after the FDA’s unapproved drugs initiative forced its approval. The company then pursued Paragraph IV litigation to enforce that position against generics. The strategy worked, at least for a period, before collapsing under political and legal pressure.<\/p>\n\n\n\n

\n\n\n\n

The Commercial Logic: When Indication Expansion Pencils Out<\/strong><\/h2>\n\n\n\n

The Investment Calculation<\/strong><\/h3>\n\n\n\n

Running a Phase III clinical trial for a new indication in a mature molecule is not cheap. Depending on the disease area, patient population size, and regulatory requirements, it can cost anywhere from $50 million to $500 million or more. The question is whether the resulting exclusivity protection justifies that investment.<\/p>\n\n\n\n

The answer depends on four variables: the size of the new market, the probability of trial success, the duration and enforceability of the resulting exclusivity, and the competitive landscape in the new indication.<\/p>\n\n\n\n

A mature oncology drug with strong mechanistic rationale in an adjacent tumor type, a targeted patient population with limited treatment options, and a patent portfolio capable of extending exclusivity by seven to ten years represents a substantially different risk profile than a cardiovascular drug pursuing a marginal risk reduction in a population already well-served by generics.<\/p>\n\n\n\n

The most compelling candidates are drugs where the mechanism of action has broader-than-expected biological relevance, where preclinical signals exist in adjacent disease areas, and where the regulatory pathway is relatively well-defined. PDE5 inhibitors, which began as cardiovascular compounds before sildenafil was repositioned as Viagra and then extended to pulmonary arterial hypertension as Revatio, illustrate the strategic logic cleanly. <blockquote> ‘The global drug repurposing and repositioning market was valued at approximately $35.3 billion in 2022 and is projected to reach $76.9 billion by 2030, reflecting compound annual growth of roughly 10.2 percent.’ [1] <\/blockquote><\/p>\n\n\n\n

Signal vs. Noise in the Pipeline<\/strong><\/h3>\n\n\n\n

Most indication expansion programs do not emerge from systematic patent strategy. They emerge from clinical observations, post-marketing surveillance, mechanistic insights from academic collaborators, and occasionally from patient advocacy groups identifying unmet needs. The patent strategy comes second, as a way to protect the investment in generating clinical evidence.<\/p>\n\n\n\n

But increasingly, companies are running the calculation in reverse. Business development teams and IP counsel are asking: which of our late-stage or marketed molecules has unexploited IP life if we pursue indication X? That calculation requires integrating patent expiration timelines, trial feasibility, market size estimates, and the competitive IP landscape in the target indication.<\/p>\n\n\n\n

\n\n\n\n

Case Studies: The Anatomy of Successful Indication Expansion<\/strong><\/h2>\n\n\n\n

Humira’s Indication Cascade<\/strong><\/h3>\n\n\n\n

AbbVie’s adalimumab (Humira) is the most-studied example of indication expansion as a primary commercial strategy, though the story is typically told through the lens of its formulation and manufacturing patents. The drug was originally approved for rheumatoid arthritis in 2002. Over the following 20 years, it accumulated approvals in more than a dozen additional indications including plaque psoriasis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, hidradenitis suppurativa, and several others.<\/p>\n\n\n\n

Each new indication represented a distinct regulatory event with its own data package. Each was accompanied by method-of-use patents claiming the treatment of the specific disease. By the time the compound’s primary U.S. patents approached expiration, Humira’s Orange Book listing contained over 130 patents, spanning a range of expiration dates.<\/p>\n\n\n\n

Biosimilar manufacturers attempting to enter the U.S. market had to navigate not just the formulation and concentration patents but also the method-of-use patents for every indication their biosimilar sought to reference. AbbVie’s settlement agreements with most major biosimilar developers delayed U.S. launch to January 2023, while European biosimilars had entered years earlier. The indication patent estate was one component of that leverage.<\/p>\n\n\n\n

The Humira case illustrates both the power of the strategy and its reputational risks. Congressional scrutiny of AbbVie’s patent practices around adalimumab contributed directly to provisions in the Inflation Reduction Act targeting pharmaceutical pricing. The indication patents were part of the political story, even if the legal mechanisms preventing biosimilar entry were primarily the settlement agreements rather than court-sustained patent claims.<\/p>\n\n\n\n

Revatio: The Cardiovascular Conversion<\/strong><\/h3>\n\n\n\n

Sildenafil’s history begins in cardiovascular research. Pfizer was investigating the compound as a treatment for hypertension and angina pectoris. When clinical trials showed limited efficacy for those conditions but unexpected effects on penile erection, Pfizer pivoted to erectile dysfunction, obtained approval as Viagra in 1998, and built one of the best-selling drugs in pharmaceutical history.<\/p>\n\n\n\n

The compound patent for sildenafil expired in the United States in 2012. But Pfizer had also pursued clinical trials in pulmonary arterial hypertension (PAH), a rare and serious condition. The FDA approved Revatio (sildenafil) for PAH in 2005. The resulting orphan drug designation and method-of-use patent estate created a separate protected position in the PAH market that survived the compound patent expiration.<\/p>\n\n\n\n

When generic sildenafil entered the Viagra market in 2017, Revatio’s PAH indication continued to carry separate IP protection. Generics could manufacture sildenafil. They could not automatically capture the PAH indication without navigating Revatio’s patent estate. The mechanism was precisely the one this article describes: using a method-of-use patent and regulatory exclusivity for a new indication to carve out a protected position in a segment of the market.<\/p>\n\n\n\n

Eliquis and the Atrial Fibrillation-to-VTE Expansion<\/strong><\/h3>\n\n\n\n

Bristol-Myers Squibb and Pfizer’s apixaban (Eliquis) received its first FDA approval for reducing stroke risk in atrial fibrillation in 2012, then for deep vein thrombosis and pulmonary embolism treatment and prevention. The multi-indication strategy gave the drug different approved uses, different patient populations, and different prescribing contexts, each supported by its own clinical trial package and IP position.<\/p>\n\n\n\n

When generic manufacturers filed Paragraph IV certifications against Eliquis, they faced a patent estate that included method-of-use patents tied to specific approved indications. Mylan (now Viatris) and others filed challenges beginning around 2017. The litigation eventually resolved through settlements keeping generics out until 2026 or later for some claims. The method-of-use patents covering atrial fibrillation treatment were part of the asserted estate.<\/p>\n\n\n\n

Keytruda’s Indication Proliferation<\/strong><\/h3>\n\n\n\n

Merck’s pembrolizumab (Keytruda) has arguably taken indication expansion further than any drug in oncology history. From its initial approval in advanced melanoma in 2014, Keytruda has accumulated over 40 indications across multiple tumor types, including non-small cell lung cancer, head and neck squamous cell carcinoma, colorectal cancer, endometrial carcinoma, and others.<\/p>\n\n\n\n

Each approved indication represents a distinct regulatory event. Each comes with method-of-use patent filings claiming the treatment of that specific cancer type, often with claims specifying biomarker-selected patient populations such as PD-L1 expression levels or tumor mutational burden thresholds. The specificity of those biomarker claims is worth noting: a competitor seeking to challenge the patent cannot simply argue that pembrolizumab does not work in the tumor type. They must engage with whether the claimed biomarker selection constitutes patentable subject matter or adequate description.<\/p>\n\n\n\n

The proliferation of indications also serves a commercial purpose beyond IP. Each indication represents a different contracting relationship with payers, a different clinical guideline update, and a different sales force deployment. The compound is the same. The commercial footprint is multiplied.<\/p>\n\n\n\n

\n\n\n\n

The Patent Mechanics: How Methods-of-Use Claims Are Structured<\/strong><\/h2>\n\n\n\n

Claim Architecture<\/strong><\/h3>\n\n\n\n

A well-drafted method-of-use patent claim specifies several elements that collectively define the protected method. These typically include the active ingredient, the patient population (defined by disease, biomarker, or prior treatment history), the dosing regimen in many cases, and the therapeutic outcome being claimed.<\/p>\n\n\n\n

The specificity of claim drafting is strategically consequential. Narrow claims are harder to challenge but easier to design around. Broad claims cover more commercial territory but face greater invalidity risk under Section 102 (anticipation) and Section 103 (obviousness), particularly when the prior art includes clinical case reports, conference presentations, or prior-filed patents from academic investigators who were studying the molecule in the same disease.<\/p>\n\n\n\n

The obviousness challenge is the most common attack on method-of-use patents. A generic manufacturer will argue that given the drug’s known mechanism and the published literature on the disease biology, it would have been obvious to a person of ordinary skill to try the compound in this indication. The branded company responds by pointing to unexpected efficacy results, failed prior art, or evidence that the claimed dosing regimen was non-obvious.<\/p>\n\n\n\n

The secondary considerations of non-obviousness, including commercial success, long-felt unmet need, and failure of others, are particularly relevant for indication expansion patents. If dozens of other companies tried to crack a therapeutic indication for years and failed, and the branded company succeeded with a known compound, that failure of others is evidence of non-obviousness.<\/p>\n\n\n\n

Orange Book Listing and the 30-Month Stay<\/strong><\/h3>\n\n\n\n

Under Hatch-Waxman, a branded company that receives a Paragraph IV certification challenging an Orange Book-listed patent has 45 days to file a patent infringement lawsuit. If it does, a 30-month stay automatically prevents the FDA from granting final approval to the generic ANDA, absent a court ruling in the generic’s favor.<\/p>\n\n\n\n

The 30-month stay is the mechanism that converts methods-of-use patent listings into commercial leverage. It is not free: the branded company must file and litigate the case. But even if the patent is ultimately found invalid or not infringed, the stay buys time. In a drug generating $2 billion annually, 30 months of additional exclusivity is worth roughly $5 billion in gross revenue, less the cost of litigation.<\/p>\n\n\n\n

The FDA can only list method-of-use patents that claim an approved method of using the drug in the approved indication. The agency does not evaluate whether the patent is valid or actually covers what it says. It relies on the sponsor’s good-faith certification that the patent meets listing requirements. That creates an incentive to list aggressively, and companies do.<\/p>\n\n\n\n

Section viii Carveouts and Their Limitations<\/strong><\/h3>\n\n\n\n

When a generic manufacturer believes a listed method-of-use patent does not cover its proposed labeling, it can file a ‘section viii statement’ instead of a Paragraph IV certification. A section viii statement says, in effect: ‘We acknowledge this patent exists, but our label carves out the patented use.’ The generic requests that the FDA approve its label with the patented indication removed.<\/p>\n\n\n\n

This is called a skinny label. It allows generics to enter the market for non-patented uses while nominally leaving the branded indication to the brand. The strategy has worked for some drugs but has faced serious legal challenges.<\/p>\n\n\n\n

The Teva v. GlaxoSmithKline litigation over carvedilol (Coreg) in the Federal Circuit illustrates the risk. GSK held a method-of-use patent covering the use of carvedilol to decrease mortality in heart failure patients. Teva filed a section viii carveout and launched with a skinny label omitting that indication. GSK sued for induced infringement, arguing that Teva’s labeling, marketing materials, and communications to physicians effectively encouraged the patented use even without explicit labeling.<\/p>\n\n\n\n

The Federal Circuit, in a 2021 decision, found Teva liable for induced infringement. The court’s reasoning relied substantially on Teva’s communication with physicians about Coreg’s established use in heart failure, which physicians would associate with the patented method regardless of what the label said. The decision created significant uncertainty about the viability of skinny labels and, by extension, the practical benefit of method-of-use carveouts.<\/p>\n\n\n\n

\n\n\n\n

Tracking the Landscape: The Intelligence Problem<\/strong><\/h2>\n\n\n\n

Why Standard Patent Searches Miss the Picture<\/strong><\/h3>\n\n\n\n

Any sophisticated patent search will return the compound patents for a given molecule. What analysts frequently underestimate is the density and diversity of the method-of-use patent estate and, critically, the mapping between specific Orange Book listings and specific approved indications.<\/p>\n\n\n\n

A compound may have ten or twelve method-of-use patents. Each was filed at a different time, with different claim scope, and each is associated with a different regulatory event. The expiration dates scatter across a decade or more. Some are listed in the Orange Book. Some are not yet listed because they were filed speculatively for indications still in development. Some have been challenged in post-grant proceedings at the Patent Trial and Appeal Board (PTAB) and have narrowed claims or surviving claims.<\/p>\n\n\n\n

Assembling this picture from scratch requires coordinating patent database searches, Orange Book lookups, PTAB records, district court dockets, and FDA regulatory documents. The effort is substantial, and it must be repeated continuously as the estate evolves.<\/p>\n\n\n\n

How DrugPatentWatch Addresses This<\/strong><\/h3>\n\n\n\n

DrugPatentWatch has built a database specifically designed to integrate these disparate data streams for pharmaceutical patent analysis. Rather than forcing analysts to stitch together patent databases, FDA records, and litigation filings manually, the platform maps approved drug products to their Orange Book patent listings, tracks patent expiration timelines by indication, monitors PTAB proceedings and litigation outcomes, and aggregates generic ANDA filings and Paragraph IV certifications.<\/p>\n\n\n\n

For method-of-use patent analysis specifically, DrugPatentWatch lets users see which indications for a given drug are still under patent protection, which patents are being challenged, and how the expiration timeline of a drug’s total exclusivity position compares to the primary compound patent expiration. That distinction between compound patent expiration and full exclusivity expiration is precisely what naive patent cliff analyses miss.<\/p>\n\n\n\n

Investment analysts using DrugPatentWatch have been able to identify situations where a drug’s consensus-estimated generic entry date significantly understates the true exclusivity horizon because of unrecognized method-of-use patents. The information advantage translates directly into better models.<\/p>\n\n\n\n

\n\n\n\n

Competitive Dynamics: How Rivals and Generics Respond<\/strong><\/h2>\n\n\n\n

The PTAB Challenge Route<\/strong><\/h3>\n\n\n\n

Inter partes review (IPR) proceedings at the PTAB have become the first-choice offensive tool for generic manufacturers challenging Orange Book-listed patents, including method-of-use claims. The PTAB applies a different claim construction standard than district courts did historically (though the gap has narrowed since the adoption of the Phillips standard in IPR), and its invalidation rate for pharma patents has historically been substantial.<\/p>\n\n\n\n

For method-of-use patents, the most common IPR ground is obviousness. The petitioner identifies prior art, typically including published clinical studies, conference abstracts, and prior-filed patents, showing that the therapeutic use was known or suggested before the priority date. The patent owner responds with objective indicia of non-obviousness and factual arguments about what the prior art actually taught or suggested.<\/p>\n\n\n\n

PTAB statistics consistently show that pharma and biotech method claims survive institution at lower rates than apparatus or composition claims [2]. That reflects the breadth of the prior art available to challengers when a molecule has years of published literature before the method-of-use filing.<\/p>\n\n\n\n

Follow-On Indication Racing<\/strong><\/h3>\n\n\n\n

When a branded company pursues a new indication for a mature molecule, competitors pay close attention. If the indication is large enough and the mechanism is broad enough, multiple companies may be running parallel clinical programs in adjacent spaces.<\/p>\n\n\n\n

The race to identify and patent the optimal biomarker selection criteria, dosing regimen, or patient subpopulation creates what can become a crowded IP landscape within a single therapeutic class. The PD-1\/PD-L1 checkpoint inhibitor space illustrates this: Merck, Bristol-Myers Squibb, AstraZeneca, Roche, and others all pursued overlapping tumor type approvals with partially overlapping IP claims. The result has been multi-party litigation over method-of-use claims in oncology, with settlements and licensing agreements shaping the competitive dynamics as much as the underlying science.<\/p>\n\n\n\n

Licensing as a Competitive Tool<\/strong><\/h3>\n\n\n\n

Not every response to a competitor’s method-of-use position involves litigation or carveout strategies. Licensing is often the preferred path when the patent holder has a strong position and the challenger has legitimate commercial ambitions.<\/p>\n\n\n\n

Cross-licensing arrangements between branded companies in the same indication, where each holds different aspects of the method, are common in oncology combinations. Licensing to biosimilar developers in exchange for revenue-sharing arrangements rather than litigation has become the preferred exit ramp for several high-profile biologic estates.<\/p>\n\n\n\n

\n\n\n\n

The Biologics Dimension: Biosimilar Strategy and Method-of-Use Patents<\/strong><\/h2>\n\n\n\n

How the BPCIA Changes the Calculation<\/strong><\/h3>\n\n\n\n

The regulatory framework for biologics exclusivity differs from Hatch-Waxman in important respects that affect how method-of-use patents operate in the biosimilar space.<\/p>\n\n\n\n

The BPCIA’s ‘patent dance’ requires the reference product sponsor (the innovator biologic company) and the biosimilar applicant to exchange patent information and engage in a process for identifying which patents to litigate. Method-of-use patents are among the patents that can be identified in this exchange. Unlike Hatch-Waxman’s automatic 30-month stay, the BPCIA requires the parties to negotiate or litigate which patents are included in the first wave of litigation.<\/p>\n\n\n\n

This creates a more complex negotiating dynamic. The reference product sponsor wants to maximize the number of patents litigated in the first wave, including method-of-use claims for every approved indication. The biosimilar applicant wants to minimize litigation scope and focus on the most commercially important patents.<\/p>\n\n\n\n

Indications as Competitive Moats in Biologics<\/strong><\/h3>\n\n\n\n

For biologics with large numbers of approved indications, the method-of-use patent estate functions as a series of overlapping moats. A biosimilar that obtains approval for rheumatoid arthritis but wants to also capture the market for Crohn’s disease must navigate the Crohn’s-specific method patents separately. The clinical interchangeability designation from the FDA applies product-wide but does not resolve patent questions.<\/p>\n\n\n\n

AbbVie’s management of the Humira biosimilar situation showed how indication-specific patents can be incorporated into broader settlement negotiations. Settlement agreements with biosimilar developers often included different launch dates for different indications, reflecting the varying strength of the underlying IP in each disease area. Sandoz, for example, agreed to certain market access conditions that differed from terms agreed with Amgen or Boehringer Ingelheim.<\/p>\n\n\n\n

\n\n\n\n

Regulatory Strategy: Designing the sNDA for Maximum IP Value<\/strong><\/h2>\n\n\n\n

Crafting the Label<\/strong><\/h3>\n\n\n\n

The approved label is the foundation on which method-of-use Orange Book listings rest. A label that describes a specific treatment algorithm, including patient selection criteria, dosing sequence, and co-administration requirements, supports more specific patent claims than a broad approval in a disease category.<\/p>\n\n\n\n

Companies that are serious about IP strategy work to ensure that their clinical development program generates data that supports specific, protectable claims. If the Phase III trial uses a biomarker-defined population, the label reflects that. If the dosing optimization work shows that a particular regimen achieves outcomes that a simpler regimen does not, that regimen goes in the label, and the patent claims cover it.<\/p>\n\n\n\n

This alignment between clinical development, regulatory strategy, and IP strategy requires organizational coordination that many pharma companies do not achieve. Clinical development leaders focus on winning approval. Regulatory affairs focuses on label negotiation. Patent counsel focuses on claim drafting. When these functions do not communicate during the development process, opportunities are lost.<\/p>\n\n\n\n

The Timing Problem<\/strong><\/h3>\n\n\n\n

Patent applications must be filed before the priority date to capture the relevant disclosure. For indication expansion programs, that means patent applications covering the new method must be filed before the clinical data is published, before conference presentations, and well before the NDA submission.<\/p>\n\n\n\n

A company that runs a successful Phase III trial, publishes the results in the New England Journal of Medicine, presents at a major medical conference, and then asks its patent department to file method-of-use claims has potentially destroyed the novelty of those claims through its own prior art. The one-year grace period under U.S. patent law (post-AIA, for the inventor’s own disclosures) provides some buffer, but it does not apply to international patents, where absolute novelty is required in most jurisdictions.<\/p>\n\n\n\n

Coordinating patent filing with publication embargo management is standard practice at large pharma companies. It is less consistently implemented at biotech companies and academic medical centers that may own rights in a discovery but lack the IP infrastructure to capture it properly.<\/p>\n\n\n\n

\n\n\n\n

International Dimensions: Protecting New Indications Outside the United States<\/strong><\/h2>\n\n\n\n

European Patent Office Practice<\/strong><\/h3>\n\n\n\n

The European Patent Convention permits method-of-treatment claims only under specific provisions, because the EPC historically excluded methods of treatment of the human body from patentability under what is now Article 53(c). The practical workaround is ‘purpose-limited product claims’ or ‘Swiss-type claims,’ which protect the use of a known substance for manufacture of a medicament for treating a specified disease.<\/p>\n\n\n\n

Under EPC 2000, Article 54(5) allows ‘second medical use’ claims directly, covering the use of a known compound for a new therapeutic application. These claims have the same practical effect as method-of-use claims in the United States but are structurally different.<\/p>\n\n\n\n

European method-of-treatment claim practice matters because branded companies that want global protection for a new indication must navigate both U.S. and European claim types. Failure to file adequately in Europe, or filing claims that are too narrow to withstand EPO examination, leaves the new indication exposed to competition in major markets regardless of U.S. protection.<\/p>\n\n\n\n

Supplementary Protection Certificates<\/strong><\/h3>\n\n\n\n

Within the European Union, supplementary protection certificates (SPCs) extend patent protection for pharmaceutical products by up to five years to compensate for the time spent in regulatory development. SPCs are available for new active ingredients but their availability for new indications is more limited. The EU SPC regulation requires that the SPC protect a ‘product’ covered by a basic patent, and the scope of that protection has been litigated extensively, including before the Court of Justice of the European Union in cases like Actavis v. Sanofi and Teva v. Gilead.<\/p>\n\n\n\n

For indication expansion strategies, the relevant question is whether the new method-of-use patent constitutes the ‘basic patent’ needed to support an SPC application for the approved product. The answer depends on claim language and is not always favorable to the brand holder.<\/p>\n\n\n\n

\n\n\n\n

The Role of Academia and the Bayh-Dole Act<\/strong><\/h2>\n\n\n\n

University IP as an Input<\/strong><\/h3>\n\n\n\n

A substantial fraction of indication expansion programs trace back to academic discoveries. A university laboratory identifies a novel application for an approved drug, publishes promising preclinical results, and the pharmaceutical company licenses the IP or enters a sponsored research agreement.<\/p>\n\n\n\n

The Bayh-Dole Act of 1980 allows universities receiving federal research funding to retain ownership of resulting inventions and license them to commercial parties. That framework has made universities active participants in the method-of-use patent ecosystem. Institutions like Johns Hopkins, Memorial Sloan Kettering, and the University of California system regularly hold method-of-use patents on therapeutic applications of approved drugs.<\/p>\n\n\n\n

For pharmaceutical companies scouting for indication expansion opportunities, university patent portfolios are a key input. A drug company that identifies an academic patent claiming the use of its approved compound in a new disease, and that recognizes the clinical plausibility of the claim, faces a classic buy-or-fight decision: license the academic IP and build on it, or challenge the patent’s validity.<\/p>\n\n\n\n

NIH and the March-In Rights Debate<\/strong><\/h3>\n\n\n\n

When federal funding contributed to the development of a pharmaceutical product, the Bayh-Dole Act grants the federal government march-in rights: the ability to license the technology to third parties if the rights holder is not making the invention adequately available to the public on reasonable terms.<\/p>\n\n\n\n

March-in rights have never been successfully invoked to override pharmaceutical pricing, though there have been multiple petitions requesting their use on drugs including Xtandi (enzalutamide) and Norvir (ritonavir). The Biden administration’s 2023 guidance on march-in rights explicitly raised pricing as a potential criterion, creating uncertainty. For method-of-use patents that trace to federally funded research, that uncertainty is relevant IP risk.<\/p>\n\n\n\n

\n\n\n\n

The PTAB Record: What Post-Grant Proceedings Tell Us<\/strong><\/h2>\n\n\n\n

IPR Outcomes in Pharma Method Claims<\/strong><\/h3>\n\n\n\n

The Patent Trial and Appeal Board’s data on pharmaceutical patent cases shows distinct patterns for method-of-use claims compared to compound or formulation patents. From 2012 through 2024, the institution rate for pharma method-of-use IPR petitions has been somewhat lower than for device or software patents, reflecting the technical complexity of the clinical evidence.<\/p>\n\n\n\n

When IPRs on method patents are instituted, final written decisions show invalidation rates that vary significantly by claim type. Broad method claims covering well-studied disease areas with substantial prior art have fared poorly. Narrow claims covering biomarker-defined populations or specific combination regimens with limited prior art support have survived more frequently.<\/p>\n\n\n\n

The Janssen Pharmaceuticals IPR battles over paliperidone palmitate (Invega Sustenna) provide an instructive data point. Generics filed multiple IPR petitions challenging Janssen’s method-of-use and dosing regimen patents. The PTAB instituted review on several claims. Janssen prevailed on some and lost on others, ultimately settling the litigation in a manner that preserved meaningful exclusivity while allowing some generic entry.<\/p>\n\n\n\n

The Fintiv Doctrine and Its Aftermath<\/strong><\/h3>\n\n\n\n

The Apple v. Fintiv doctrine, which the PTAB used from 2020 onward to deny institution of IPR petitions when parallel district court litigation was advanced, had significant effects on pharma patent challenges. When a branded company filed Hatch-Waxman litigation shortly after a Paragraph IV certification and the district court scheduled a trial date within a year or two, generics found their IPR petitions denied on Fintiv grounds before the substantive merits could be reached.<\/p>\n\n\n\n

The USPTO’s 2022 guidance on Fintiv limited its application, and subsequent director review proceedings have further shaped its scope. For method-of-use patents specifically, the interplay between district court Hatch-Waxman timelines and PTAB IPR institution decisions remains an active strategic variable.<\/p>\n\n\n\n

\n\n\n\n

Pricing Strategy and the Indication Premium<\/strong><\/h2>\n\n\n\n

Indication-Based Pricing in the U.S. Market<\/strong><\/h3>\n\n\n\n

Method-of-use patents and regulatory exclusivity for new indications do more than extend the period during which the brand can charge a premium. They also support indication-specific pricing strategies that would be difficult to implement without exclusivity protection.<\/p>\n\n\n\n

Indication-based pricing, sometimes called outcome-based or value-based pricing, involves charging different prices for the same drug depending on which condition it treats, reflecting the different clinical value in each context. Pfizer implemented a version of this for palbociclib (Ibrance) in breast cancer versus, theoretically, other oncology indications it might pursue. Novartis explored indication-based pricing frameworks for Entresto in heart failure and for certain oncology agents.<\/p>\n\n\n\n

The practical challenge is that U.S. pharmacy systems are not built for indication-based pricing at the point of dispensing. Drugs are priced by NDC code, not by diagnosis. Implementing true indication differentiation requires complex payer contracting mechanisms. Still, the existence of separate regulatory approvals and method-of-use patents for different indications gives manufacturers legal justification for different contract terms with different payer cohorts, effectively achieving indication-based pricing outcomes through contracting even when the pharmacy system sees a single price.<\/p>\n\n\n\n

Inflation Reduction Act: The Drug Price Negotiation Overlay<\/strong><\/h3>\n\n\n\n

The Inflation Reduction Act’s drug price negotiation provisions, first applicable in 2026, add a new variable to the indication expansion calculus. Medicare price negotiation applies to drugs that have been on the market for at least nine years (small molecules) or thirteen years (biologics) without generic or biosimilar competition.<\/p>\n\n\n\n

The presence of method-of-use patents maintaining exclusivity against generics is precisely what keeps a drug within the negotiation universe. If generics had entered and the branded drug’s Medicare market share had dropped, it might exit the negotiation-eligible pool. A drug maintained under exclusivity through active method-of-use patent enforcement stays in the pool and becomes subject to negotiated prices that can be significantly below list.<\/p>\n\n\n\n

For drugs like Enbrel, Eliquis, and others where extended exclusivity has been maintained through indication and formulation patents, IRA negotiation is now a direct cost of that strategy. Companies must model the IRA-discounted revenue in the later years of the extended exclusivity period to assess whether indication expansion still generates positive returns.<\/p>\n\n\n\n

\n\n\n\n

The Business Development Angle: Licensing In vs. Building Out<\/strong><\/h2>\n\n\n\n

Acquiring Indication Expansion Opportunities<\/strong><\/h3>\n\n\n\n

Not every company that benefits from a method-of-use patent ran the clinical trial that justified it. Business development deals frequently involve the acquisition of late-stage or approved supplemental indications from smaller companies that ran the trial but lack the commercial infrastructure to monetize the approval fully.<\/p>\n\n\n\n

Bristol-Myers Squibb’s acquisition of Celgene, completed in 2019 for $74 billion, brought with it not just approved compounds but an extensive portfolio of ongoing indication expansion programs for ozanimod, lisocabtagene maraleucel, and ide-cel, among others. Each program represented potential future method-of-use patents layered on top of the acquired compound estates.<\/p>\n\n\n\n

The valuation question in these deals is complex: a company with three approved indications and eight clinical programs for new indications in a compound with 15 years of remaining compound patent life has a very different IP profile than a company with one approved indication and a patent expiring in four years. Modeling the expected value of the indication expansion pipeline requires exactly the kind of patent-to-regulatory mapping that tools like DrugPatentWatch enable.<\/p>\n\n\n\n

Partnership Structures in Indication Development<\/strong><\/h3>\n\n\n\n

Co-development agreements for new indications have become common, particularly in oncology, where combination regimens require both companies to contribute clinical data for a trial involving both drugs. These agreements raise IP questions that are not always well-resolved: who owns the method-of-use patents arising from the combination trial? How are Orange Book listing rights allocated? What happens if the combination succeeds but one partner’s compound later faces generic competition?<\/p>\n\n\n\n

The Merck-Pfizer collaboration on Bavencio (avelumab) and Bristol-Myers Squibb’s various combination trial agreements have generated litigation and arbitration over these ownership questions. The commercial stakes are large enough that companies increasingly negotiate detailed IP ownership provisions for trial-generated data before they begin enrollment.<\/p>\n\n\n\n

\n\n\n\n

Institutional Capacity: Building an Indication Expansion Function<\/strong><\/h2>\n\n\n\n

The Interdisciplinary Team<\/strong><\/h3>\n\n\n\n

Successful indication expansion programs require unusual organizational coordination. Translational science must identify credible biological rationale. Clinical development must design and execute trials that are likely to generate approvable data. Regulatory affairs must interact with the FDA to define the approval pathway and negotiate label language. IP counsel must file patent applications aligned with clinical development milestones. Commercial strategy must assess the market opportunity. And all of this must happen in an integrated timeline that avoids premature disclosure, manages patent filing windows, and coordinates clinical and regulatory milestones.<\/p>\n\n\n\n

Large pharmaceutical companies address this through indication expansion committees that sit across R&D and commercial functions. Smaller biotechs often lack the bandwidth for this coordination and rely on outside counsel and consultants to provide IP strategy in parallel with clinical operations.<\/p>\n\n\n\n

The gap in organizational capacity partly explains why a disproportionate share of successful indication expansion programs occurs at large, established pharmaceutical companies. They have the institutional muscle to run multiple concurrent processes in a coordinated way. They also have the cash to absorb failed trials without existential consequences.<\/p>\n\n\n\n

Using External Intelligence to Prioritize<\/strong><\/h3>\n\n\n\n

Before committing to a new indication program, companies use competitive intelligence to assess the IP landscape in the target disease. If a competitor has already filed method-of-use claims covering the target disease with the company’s compound class, the first-to-file question is moot. What remains is whether the competitor’s claims can be worked around, challenged, or licensed.<\/p>\n\n\n\n

Platforms like DrugPatentWatch are integral to this competitive intelligence process. By aggregating Orange Book listings, PTAB filings, and litigation data, they let an analyst quickly assess whether the indication target is already claimed, whether existing claims are under challenge, and what the expiration timeline looks like. That assessment is an input to the go\/no-go decision on a clinical program that will cost tens or hundreds of millions of dollars.<\/p>\n\n\n\n

\n\n\n\n

Regulatory Exclusivity vs. Patent Protection: Strategic Prioritization<\/strong><\/h2>\n\n\n\n

When Regulatory Exclusivity Matters More<\/strong><\/h3>\n\n\n\n

In certain situations, regulatory exclusivity is a more reliable form of protection than patent coverage. Three-year Hatch-Waxman exclusivity for a new clinical indication is automatic upon approval, does not require litigation to enforce, and cannot be challenged through IPR or other post-grant proceedings. It is simply a statutory right that prevents FDA from granting final generic approval for the new indication during the exclusivity period.<\/p>\n\n\n\n

For drugs where the patent claims are weak, where prior art is close, or where the budget for patent litigation is limited, a strategy that emphasizes regulatory exclusivity, orphan designation where applicable, and pediatric exclusivity extensions can provide meaningful protection without the cost and uncertainty of Paragraph IV litigation.<\/p>\n\n\n\n

The Pediatric Research Equity Act (PREA) and the Best Pharmaceuticals for Children Act (BPCA) offer six months of additional exclusivity for drugs that complete qualifying pediatric studies. Six months on a drug generating $5 billion annually is $2.5 billion. Companies pursuing indication expansion in diseases that affect both adults and children can sometimes structure their development program to capture pediatric exclusivity in combination with the new indication approval.<\/p>\n\n\n\n

The Stack: How Exclusivity Layers Compound<\/strong><\/h3>\n\n\n\n

The most sophisticated indication expansion strategies produce what practitioners call ‘exclusivity stacks’: combinations of patent and regulatory protections that create an aggregate exclusivity horizon substantially longer than any single protection alone.<\/p>\n\n\n\n

A hypothetical illustrates the point. A drug with a compound patent expiring in 2025 pursues a new indication. The sNDA is approved in 2026, giving three-year Hatch-Waxman exclusivity until 2029. The new indication qualifies for orphan drug designation, adding seven years of orphan exclusivity until 2033 for that indication. The method-of-use patents covering the new indication expire in 2036 and 2038. If those patents survive PTAB challenge, the drug maintains exclusivity in the new indication 13 years after the compound patent expiration.<\/p>\n\n\n\n

That math is why indication expansion has become a core lifecycle management strategy rather than an opportunistic add-on. The numbers are large enough to justify substantial clinical investment.<\/p>\n\n\n\n

\n\n\n\n

The Litigation Battlefield: Recent Decisions Shaping the Field<\/strong><\/h2>\n\n\n\n

Amarin v. Hikma: The Skinny Label Debate<\/strong><\/h3>\n\n\n\n

The saga of icosapentaenoic acid (EPA), marketed by Amarin as Vascepa, demonstrates how sharply contested the skinny label doctrine has become in the context of method-of-use patents.<\/p>\n\n\n\n

Amarin initially received FDA approval for Vascepa in 2012 for severely elevated triglycerides. In 2019, Vascepa received an additional approval based on the REDUCE-IT trial, for reducing cardiovascular risk in adults with elevated triglycerides and established cardiovascular disease or diabetes. Amarin held method-of-use patents covering this new cardiovascular risk reduction indication.<\/p>\n\n\n\n

When generic manufacturers sought to carve out the cardiovascular indication from their labels, Amarin sued for inducement. The district court in Nevada found that Amarin had not demonstrated a likelihood of success on its inducement claims, partly because physicians could prescribe the generic for the carved-out indication without the label directing them to do so. The Federal Circuit’s subsequent rulings further shaped the analysis.<\/p>\n\n\n\n

Amarin’s failure to obtain a preliminary injunction blocking generic entry to the Vascepa market contributed to the collapse of its exclusivity position. The case is now widely cited in discussions of skinny label risk and the limitations of method-of-use patent enforcement against section viii carveouts.<\/p>\n\n\n\n

Allergan and the Tribe Patent Transfer Controversy<\/strong><\/h3>\n\n\n\n

In 2017, Allergan transferred Orange Book-listed patents for Restasis (cyclosporine ophthalmic emulsion) to the Saint Regis Mohawk Tribe, a federally recognized sovereign tribe, in an attempt to use tribal sovereign immunity to shield the patents from PTAB IPR proceedings. The patents at issue included method-of-use claims.<\/p>\n\n\n\n

The Federal Circuit rejected the tribal immunity defense in 2019, finding that IPR proceedings are not suits against the patent owner of the type to which tribal immunity applies. The decision closed what Allergan had hoped would be a creative defense against the inter partes review mechanism. The underlying method-of-use patents were subsequently found invalid in IPR proceedings, and Allergan lost the exclusivity it had sought to protect.<\/p>\n\n\n\n

The case illustrates both the value that companies ascribe to method-of-use patent estates and the lengths they will go to defend them. It also illustrates the asymmetry: if the patents had survived, Allergan would have maintained exclusivity worth billions. Once they fell, the losses were immediate and irreversible.<\/p>\n\n\n\n

Teva v. GlaxoSmithKline: Induced Infringement in Method Claims<\/strong><\/h3>\n\n\n\n

The 2021 Federal Circuit decision in Teva Pharmaceuticals USA, Inc. v. GlaxoSmithKline LLC, mentioned earlier in the context of carvedilol, deserves extended attention because of its implications for the generic industry’s skinny label strategy.<\/p>\n\n\n\n

GSK’s carvedilol patent claimed a method of decreasing mortality in patients with congestive heart failure by administering carvedilol. Teva launched with a skinny label that omitted this indication. GSK sued, arguing that Teva induced infringement by physicians who prescribed the drug knowing its heart failure benefits.<\/p>\n\n\n\n

The Federal Circuit, in a divided panel decision, found for GSK. The majority’s reasoning focused on Teva’s communications about carvedilol that were not strictly label-content but that referenced the heart failure mortality benefit. The dissent argued that the majority’s reasoning effectively eliminates the skinny label mechanism by holding generic manufacturers responsible for the knowledge base physicians bring to prescribing decisions.<\/p>\n\n\n\n

The practical effect has been to chill skinny label filings and make generic manufacturers more conservative about which indications they attempt to carve out. That, in turn, strengthens the leverage of method-of-use patent holders.<\/p>\n\n\n\n

\n\n\n\n

The Investor Perspective: Reading Patent Estates for Alpha<\/strong><\/h2>\n\n\n\n

Where Consensus Valuations Fail<\/strong><\/h3>\n\n\n\n

Sell-side pharmaceutical analysis typically models a drug’s revenue through the compound patent expiration date and then assumes a generic entry cliff. Analysts who follow this model undervalue drugs with robust method-of-use patent estates for new indications and overvalue drugs whose primary patents are weaker than they appear.<\/p>\n\n\n\n

The error is systematic. It stems from the complexity of parsing Orange Book listings, the difficulty of assessing PTAB challenge risk for individual method-of-use patents, and the lack of a convenient summary statistic that captures the full exclusivity horizon. Wall Street models are built on clean data and simple assumptions. Pharmaceutical IP is neither.<\/p>\n\n\n\n

Investors who invest the analytical effort to accurately map a drug’s full exclusivity horizon can identify situations where the consensus expected generic entry date is off by several years. For a large-cap pharmaceutical stock, that error creates an opportunity.<\/p>\n\n\n\n

Signals to Watch<\/strong><\/h3>\n\n\n\n

Specific indicators suggest that a drug’s method-of-use patent position is likely stronger than consensus assumptions reflect. First, an Orange Book listing that includes patents expiring substantially after the compound patent, specifically tied to distinct indications. Second, a clinical pipeline that includes multiple ongoing indication expansion programs, each of which represents a potential future IP filing. Third, a history of successful Hatch-Waxman litigation on method-of-use claims.<\/p>\n\n\n\n

Conversely, indicators of weakness include a dense prior art environment in the new indication, pending PTAB IPR proceedings against the method-of-use patents, a section viii carveout strategy successfully employed by generic manufacturers, and federal circuit decisions limiting induced infringement liability in analogous cases.<\/p>\n\n\n\n

DrugPatentWatch provides the data inputs to evaluate most of these indicators without building the analytical infrastructure from scratch. For buy-side analysts doing pharmaceutical IP diligence, it is a standard part of the workflow.<\/p>\n\n\n\n

\n\n\n\n

Emerging Trends: Where the Field Is Going<\/strong><\/h2>\n\n\n\n

AI-Accelerated Drug Repurposing<\/strong><\/h3>\n\n\n\n

Machine learning models trained on biological network data, gene expression profiles, and clinical outcome databases are increasingly used to identify candidate indications for approved drugs. Companies like BenevolentAI, Recursion Pharmaceuticals, and Insilico Medicine have built computational platforms specifically for this purpose.<\/p>\n\n\n\n

When AI-driven repurposing identifies a new indication, the IP questions are immediate. Does the computational prediction itself constitute prior art? Is the resulting method-of-use patent obvious in view of the model’s published predictions? The courts have not squarely addressed these questions, but they will, as AI-discovered indications increasingly populate clinical development pipelines.<\/p>\n\n\n\n

The prior art question is particularly acute. If BenevolentAI publishes a preprint identifying a known drug as a candidate treatment for a new disease based on computational analysis, and a pharmaceutical company subsequently runs a trial confirming efficacy, is the method-of-use patent on the confirmed therapeutic use obvious in view of the published prediction? The answer will shape how companies manage publication of AI-derived hypotheses in relation to patent filing timelines.<\/p>\n\n\n\n

Combination Indication Strategies<\/strong><\/h3>\n\n\n\n

Fixed-dose combinations of two or more approved drugs in a new indication represent a variant of the indication expansion strategy that produces distinct IP from either component’s method-of-use patents. A combination tablet containing Drug A and Drug B, approved for a new indication, can carry method-of-use patents claiming the method of treating the disease by co-administering both compounds at specific doses.<\/p>\n\n\n\n

These combination indication patents are often more durable than single-agent method claims because the prior art for the specific combination at the specific dose in the specific disease is thinner. Challengers must show that it would have been obvious not just to use the compound but to use it in combination with the specific partner drug at the specific ratio.<\/p>\n\n\n\n

The fixed-dose combination strategy also has regulatory benefits: the FDA can grant three-year exclusivity for the combination NDA based on the clinical trials demonstrating the combination’s efficacy, even if both components are individually generic.<\/p>\n\n\n\n

The Impact of Real-World Evidence<\/strong><\/h3>\n\n\n\n

The FDA’s increasing acceptance of real-world evidence (RWE) as a basis for supplemental approvals creates new opportunities for indication expansion at lower clinical trial cost. If post-marketing data from electronic health records, claims databases, or patient registries can support a supplemental approval for a new use, the barrier to generating method-of-use IP for that use drops considerably.<\/p>\n\n\n\n

The FDA has approved several labeling expansions based primarily on RWE, including expansions for oncology drugs in rare tumor types where randomized trials are impractical. Each such expansion creates a regulatory anchor for method-of-use patent claims. Companies that are actively mining their post-marketing data for RWE-supported indication signals are pursuing indication expansion at a fraction of the historical trial cost.<\/p>\n\n\n\n

\n\n\n\n

Practical Guidance: What Companies Should Be Doing<\/strong><\/h2>\n\n\n\n

The IP Audit<\/strong><\/h3>\n\n\n\n

Any pharmaceutical company with a portfolio of marketed drugs should be conducting systematic patent audits that specifically identify unexploited indication expansion opportunities. The audit should start with the mechanistic profile of each compound, identify disease areas with plausible biological rationale for the mechanism, scan the published literature and patent databases for evidence of prior exploration, and rank opportunities by patent life available, market size, and trial feasibility.<\/p>\n\n\n\n

This audit is not the same as a standard IP review. A standard IP review tells you what patents you have. An indication expansion audit tells you what patents you could get. The two are distinct exercises with different outputs.<\/p>\n\n\n\n

Coordination Between R&D and IP<\/strong><\/h3>\n\n\n\n

The most common failure mode in indication expansion IP capture is the time lag between clinical discovery and patent filing. A company that learns from a clinical investigator that their drug is working remarkably well in an off-label use has, at that moment, a potentially patentable discovery. If the investigator publishes before the company files, the U.S. one-year grace period may protect U.S. rights but will not protect international rights.<\/p>\n\n\n\n

Internal protocols for escalating indication signals from clinical operations to patent counsel should exist at every pharmaceutical company. They are not universal. Companies that implement them reliably will capture IP that companies without them lose.<\/p>\n\n\n\n

Monitoring Competitor Estates<\/strong><\/h3>\n\n\n\n

Indication expansion strategy is partly offensive, as in pursuing new indications for your own drugs, and partly defensive, as in monitoring what indications competitors are pursuing for drugs in your space. A competitor that obtains an sNDA approval and method-of-use patents for a new indication that your drug is used off-label for has now created an IP moat around that indication that will affect your prescribing universe.<\/p>\n\n\n\n

Tracking competitor clinical pipelines, sNDA submissions, and Orange Book listings for indications relevant to your products is a continuous monitoring task. DrugPatentWatch’s alert functions and indication-level patent tracking make this more tractable than manual monitoring of FDA databases and patent office records.<\/p>\n\n\n\n

\n\n\n\n

Key Takeaways<\/strong><\/h2>\n\n\n\n

Methods-of-use patents represent one of the most defensible and commercially valuable forms of pharmaceutical IP, yet they are systematically underestimated by consensus analysis and underutilized by companies that fail to integrate IP strategy into their clinical development processes.<\/p>\n\n\n\n

The compound patent cliff is real, but it is not the end of the exclusivity story for drugs with credible indication expansion opportunities. A molecule with a dead compound patent and three or four approved indications, each backed by method-of-use patents filed at different times with different expiration dates, can maintain meaningful exclusivity for a decade or more after the compound patent falls.<\/p>\n\n\n\n

The strategic logic is sound: run the trial, win the approval, list the patents, and enforce the exclusivity. The execution requirements are demanding: interdisciplinary coordination, precise patent filing timing, robust litigation capacity, and continuous monitoring of the competitive landscape.<\/p>\n\n\n\n

Regulatory exclusivity under Hatch-Waxman, orphan drug designation, and pediatric exclusivity are complements to the patent strategy, not substitutes. The strongest positions stack all available forms of protection to create aggregate exclusivity horizons that no single mechanism could achieve alone.<\/p>\n\n\n\n

The skinny label doctrine remains contested. The Teva v. GSK carvedilol decision tilted the balance toward branded companies by expanding induced infringement liability, but subsequent litigation will continue to define the boundaries. Generic manufacturers that believe they can avoid method-of-use patent exposure through label carveouts should model the Teva ruling carefully.<\/p>\n\n\n\n

AI-accelerated repurposing will increase the volume of indication expansion programs and create new prior art questions that courts have not yet resolved. Companies pursuing AI-driven repurposing need patent filing strategies that account for the publication behavior of computational repurposing platforms.<\/p>\n\n\n\n

Investors who model pharmaceutical earnings through compound patent expiration without assessing the method-of-use patent estate will systematically misprice drugs where indication expansion has extended the effective exclusivity horizon. Tools like DrugPatentWatch exist precisely to close that analytical gap.<\/p>\n\n\n\n

\n\n\n\n

Frequently Asked Questions<\/strong><\/h2>\n\n\n\n

Q1: Can a generic manufacturer simply avoid method-of-use patent claims by targeting only the non-patented indications?<\/strong><\/p>\n\n\n\n

In theory, yes. A section viii carveout allows a generic manufacturer to seek approval with a label that omits the patented indication. In practice, the Teva v. GlaxoSmithKline carvedilol decision has made this strategy considerably riskier. The Federal Circuit found induced infringement liability where a generic manufacturer’s communications, not just its label, encouraged physicians to use the drug in the patented way. Physicians prescribe based on their knowledge of a drug’s uses, not just the generic label. If the off-patent drug is routinely used for the patented indication, a generic entering with a skinny label may still face infringement liability. Any generic manufacturer planning a skinny label strategy should obtain a detailed infringement opinion from patent counsel before launch.<\/p>\n\n\n\n

Q2: How does orphan drug designation interact with method-of-use patents when a branded company pursues a rare disease indication for an otherwise off-patent drug?<\/strong><\/p>\n\n\n\n

The two protections operate independently and complement each other. Orphan drug exclusivity under the Orphan Drug Act provides seven years of market exclusivity for the specific rare disease indication, meaning the FDA will not approve a competitor’s application for the same drug in the same disease. This exclusivity does not require a patent. Method-of-use patents, if obtained and listed in the Orange Book, provide an additional layer of protection by requiring generic manufacturers to either challenge the patent’s validity or design around it. For an off-patent compound pursuing a rare disease indication, the combination of orphan exclusivity and method-of-use patents can produce a protected position lasting 15 years or more from the date of the rare disease approval.<\/p>\n\n\n\n

Q3: What is the greatest vulnerability in a method-of-use patent, and how do companies defend against it?<\/strong><\/p>\n\n\n\n

The greatest vulnerability is obviousness under 35 U.S.C. \u00a7 103. Generic manufacturers routinely challenge method-of-use patents by arguing that the published literature on the disease biology and the drug’s known mechanism would have made the claimed treatment method obvious to a person of ordinary skill before the patent was filed. The defense relies heavily on objective indicia of non-obviousness, including unexpected results from clinical trials, failure of others to develop effective treatments for the condition prior to the patentee’s work, and commercial success attributable to the patented features. Companies with strong indication expansion patent positions invest heavily in documenting these secondary considerations contemporaneously with their clinical development, not after a challenge is filed.<\/p>\n\n\n\n

Q4: How has the Inflation Reduction Act changed the economic calculus for indication expansion programs?<\/strong><\/p>\n\n\n\n

The IRA’s Medicare drug price negotiation provisions create a meaningful headwind for drugs that maintain exclusivity through indication expansion patents. A drug that has been on the market nine or more years without generic competition enters the pool of drugs eligible for Medicare price negotiation. Extended exclusivity through method-of-use patents means the drug remains in this pool longer. Negotiated Medicare prices, which have been set at significant discounts to list in the first negotiation cycle, will reduce the revenue available in the later years of an extended exclusivity period. Companies now need to model IRA-discounted revenue in their indication expansion ROI calculations. The strategy still generates positive returns for most credible indication expansion programs, but the margin is narrower than it was before the IRA, particularly for drugs with large Medicare-aged patient populations.<\/p>\n\n\n\n

Q5: How should a small biotech with a promising compound but limited IP infrastructure approach indication expansion patent strategy?<\/strong><\/p>\n\n\n\n

The priority is to engage patent counsel with pharmaceutical prosecution experience early in the clinical development process, before any public disclosure of results. The biotech should identify filing opportunities tied to every clinical milestone, including Phase I signals, Phase II proof-of-concept data, and any post-marketing observations. The biotech should also conduct a freedom-to-operate analysis in the target indication before committing clinical resources, to ensure that a competitor has not already staked out dominant patent claims. For small biotechs, the single largest risk is self-inflicted prior art: presenting at a conference or publishing a preprint before the patent application is on file. Establishing an internal protocol that routes all proposed publications and presentations through IP counsel for review before release is the most important institutional practice a small biotech can adopt.<\/p>\n\n\n\n

\n\n\n\n

References<\/strong><\/h2>\n\n\n\n

[1] Grand View Research. (2023). Drug repurposing and repositioning market size, share & trends analysis report by therapeutic area, by technology, by region, and segment forecasts, 2023\u20132030<\/em>. Grand View Research. https:\/\/www.grandviewresearch.com\/industry-analysis\/drug-repurposing-repositioning-market<\/p>\n\n\n\n

[2] Vishnubhakat, S., Rai, A. K., & Kesan, J. P. (2016). Strategic decision making in dual PTAB and district court proceedings. Berkeley Technology Law Journal<\/em>, 31(1), 45\u2013117. https:\/\/doi.org\/10.15779\/Z38DT2R<\/p>\n\n\n\n

[3] Federal Circuit. (2021). Teva Pharmaceuticals USA, Inc. v. GlaxoSmithKline LLC<\/em>, 7 F.4th 1320. United States Court of Appeals for the Federal Circuit.<\/p>\n\n\n\n

[4] FDA. (2023). Approved drug products with therapeutic equivalence evaluations<\/em> (Orange Book, 43rd ed.). U.S. Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/approved-drug-products-therapeutic-equivalence-evaluations-orange-book<\/p>\n\n\n\n

[5] Engelberg, A. B., Kesselheim, A. S., & Avorn, J. (2009). Balancing innovation, access, and profits: Market exclusivity for biologics. New England Journal of Medicine<\/em>, 361(20), 1917\u20131919. https:\/\/doi.org\/10.1056\/NEJMp0908496<\/p>\n\n\n\n

[6] Beall, R. F., & Kesselheim, A. S. (2019). Tertiary patenting on drug-device combination products in the United States. Nature Biotechnology<\/em>, 37(4), 384\u2013388. https:\/\/doi.org\/10.1038\/s41587-019-0061-9<\/p>\n\n\n\n

[7] Carrier, M. A. (2019). Innovation for the 21st century: Harnessing the power of intellectual property and antitrust law<\/em>. Oxford University Press.<\/p>\n\n\n\n

[8] Federal Circuit. (2019). Saint Regis Mohawk Tribe v. Mylan Pharmaceuticals Inc.<\/em>, 896 F.3d 1322. United States Court of Appeals for the Federal Circuit.<\/p>\n\n\n\n

[9] CMS. (2023). Medicare drug price negotiation program: Revised guidance<\/em>. Centers for Medicare & Medicaid Services. https:\/\/www.cms.gov\/inflation-reduction-act\/medicare-drug-price-negotiation<\/p>\n\n\n\n

[10] USPTO. (2022). Interim procedure for discretionary denials in AIA post-grant proceedings with parallel district court litigation<\/em>. United States Patent and Trademark Office. https:\/\/www.uspto.gov\/patents\/patent-trial-and-appeal-board\/ptab-trials<\/p>\n\n\n\n

[11] Hemphill, C. S., & Sampat, B. N. (2012). Evergreening, patent challenges, and effective market life in pharmaceuticals. Journal of Health Economics<\/em>, 31(2), 327\u2013339. https:\/\/doi.org\/10.1016\/j.jhealeco.2012.01.004<\/p>\n\n\n\n

[12] Sampat, B. N., & Shadlen, K. C. (2017). Secondary pharmaceutical patenting: A global perspective. Research Policy<\/em>, 46(3), 693\u2013707. https:\/\/doi.org\/10.1016\/j.respol.2017.01.005<\/p>\n\n\n\n

[13] Federal Circuit. (2021). Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc.<\/em>, 449 F. Supp. 3d 967 (D. Nev. 2020), aff’d in part, 578 F. Supp. 3d 642. United States Court of Appeals for the Federal Circuit.<\/p>\n\n\n\n

[14] Pharmaceutical Research and Manufacturers of America (PhRMA). (2023). 2023 PhRMA annual membership survey<\/em>. PhRMA. https:\/\/www.phrma.org<\/p>\n\n\n\n

[15] Hollis, A. (2004). Me-too drugs: Is there a problem?<\/em> WHO Commission on Intellectual Property Rights, Innovation and Public Health. World Health Organization. https:\/\/www.who.int\/intellectualproperty\/topics\/ip\/Me-tooDrugs_Hollis1.pdf<\/p>\n","protected":false},"excerpt":{"rendered":"

Methods-of-use patents have quietly become the pharmaceutical industry’s most underappreciated exclusivity tool. Here’s how they work, who’s using them, and […]<\/p>\n","protected":false},"author":1,"featured_media":38502,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-38499","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38499","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=38499"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38499\/revisions"}],"predecessor-version":[{"id":38503,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38499\/revisions\/38503"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/38502"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=38499"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=38499"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=38499"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}